Liposarcoma

Atypical lipomatous tumor (ALT) versus well-differentiated liposarcoma (WDLS): These are the SAME entity. Extremity/superficial lesions are called ALT due to negligible metastatic potential. Deep-seated retroperitoneal lesions are called WDLS due to higher recurrence risk from incomplete excision. Both show MDM2 amplification.

When a deep fatty tumour cannot be confidently called benign on imaging, MDM2 amplification by FISH is the decisive test: positive supports well-differentiated/dedifferentiated liposarcoma, negative argues for lipoma or another mimic. CDK4 co-amplification adds specificity.

Myxoid liposarcoma is uniquely radiosensitive among soft tissue sarcomas. Radiotherapy produces excellent local control and may achieve near-complete pathological response. This is attributed to FUS-DDIT3 fusion affecting DNA repair mechanisms. Radiation is standard adjuvant therapy for myxoid subtype.

The topic uses MDM2/CDK4 amplification purely to diagnose well-differentiated/dedifferentiated liposarcoma, but the same amplicon is the rationale for targeted therapy - a higher-board and "future-directions" point worth holding:

• The 12q13-15 amplicon that defines WD/DD liposarcoma co-amplifies MDM2 (which degrades p53) and CDK4 (which drives the cell cycle via Rb). Both are druggable.
• CDK4/6 inhibitors (e.g. palbociclib, abemaciclib) have shown progression-free-survival benefit in CDK4-amplified WD/DD liposarcoma - relevant precisely because conventional cytotoxic chemotherapy is largely ineffective in well-differentiated disease.
• MDM2 inhibitors (restoring p53 activity) are in clinical trials for MDM2-amplified liposarcoma, and trabectedin/eribulin retain a role in advanced disease (with trabectedin especially active in the myxoid subtype, as above).
• The unifying concept: in liposarcoma the diagnostic molecular marker is increasingly also the therapeutic target, which is why molecular confirmation matters beyond classification.

Exam point: in advanced/unresectable WD-DD liposarcoma where standard chemotherapy underperforms, the MDM2-CDK4 amplicon offers targeted options - CDK4/6 inhibitors (palbociclib) and trial-stage MDM2 inhibitors - so the marker that diagnoses the tumour can also guide treatment.

The topic notes in passing that myxoid liposarcoma can spread to "bone and soft tissue, not just lung", but this is a high-yield teaching point in its own right because it overturns the usual sarcoma surveillance assumption:

• Most soft tissue sarcomas metastasise haematogenously to the LUNG, so a CT chest is the standard screen. Myxoid liposarcoma is the classic exception - it has a striking tendency to spread to extrapulmonary / soft-tissue sites and BONE, particularly the SPINE/paraspinal soft tissue, retroperitoneum and other fat-bearing regions, sometimes before (or without) lung disease.
• These bony/soft-tissue deposits are frequently occult on CT and on bone scan (myxoid deposits can be lytic/non-mineralised and PET-variable), so whole-body MRI (or at least spine/abdomen-pelvis MRI) is increasingly recommended for staging and surveillance of myxoid liposarcoma rather than relying on CT chest alone.
• The round-cell (hypercellular, high-grade) component drives this metastatic risk - higher round-cell percentage means a stronger case for extended cross-sectional surveillance.

Exam point: for myxoid liposarcoma, do not limit surveillance to CT chest - it characteristically metastasises to extrapulmonary soft tissue and bone (especially the spine), so add whole-body or spine/abdomino-pelvic MRI, and raise that vigilance further with a significant round-cell component.

All major bodies agree on biopsy-before-resection, wide negative margins, and management within a sarcoma MDT. The key area of genuine divergence is retroperitoneal radiotherapy: after the STRASS trial, routine preoperative radiotherapy is no longer recommended for primary retroperitoneal sarcoma, whereas radiotherapy retains a clear role in high-risk extremity disease.